vs
ARDELYX, INC.（ARDX）とBRC Group Holdings, Inc.（RILY）の財務データ比較。上の社名をクリックして会社を切り替えられます
BRC Group Holdings, Inc.の直近四半期売上が大きい（$188.3M vs $125.2M、ARDELYX, INC.の約1.5倍）。BRC Group Holdings, Inc.の純利益率が高く（47.9% vs -0.3%、差は48.3%）。ARDELYX, INC.の前年同期比売上増加率が高い（7.8% vs -21.9%）。過去8四半期でARDELYX, INC.の売上複合成長率が高い（64.9% vs -15.4%）
アーデリックス社は商業化段階のバイオ医薬品企業で、消化器疾患、心腎疾患、代謝疾患などの医療ニーズが満たされていない疾患向け革新的治療薬の開発・販売に注力しています。米国で便秘型過敏性腸症候群向け承認薬を販売し、各段階の候補薬からなるパイプラインを保有しています。
ARDX vs RILY — 直接比較
売上が大きい
RILY
1.5倍大きい
$125.2M
売上成長率が高い
ARDX
+29.7%の差
-21.9%
純利益率が高い
RILY
純利益率が48.3%高い
-0.3%
2年売上CAGRが高い
ARDX
2年複合成長率
-15.4%
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $125.2M | $188.3M |
| 純利益 | $-407.0K | $90.3M |
| 粗利率 | 91.3% | 79.5% |
| 営業利益率 | 4.1% | 32.3% |
| 純利益率 | -0.3% | 47.9% |
| 売上前年比 | 7.8% | -21.9% |
| 純利益前年比 | -108.8% | 1710.8% |
| EPS（希薄化後） | $-0.01 | $2.78 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
売上ARDXRILY
| Q4 25 | $125.2M | $188.3M | ||
| Q3 25 | $110.3M | $215.3M | ||
| Q2 25 | $97.7M | $188.2M | ||
| Q1 25 | $74.1M | $197.2M | ||
| Q4 24 | $116.1M | $241.0M | ||
| Q3 24 | $98.2M | $225.5M | ||
| Q2 24 | $73.2M | $256.0M | ||
| Q1 24 | $46.0M | $263.4M |
純利益ARDXRILY
| Q4 25 | $-407.0K | $90.3M | ||
| Q3 25 | $-969.0K | $91.1M | ||
| Q2 25 | $-19.1M | $139.5M | ||
| Q1 25 | $-41.1M | $-10.0M | ||
| Q4 24 | $4.6M | $-5.6M | ||
| Q3 24 | $-809.0K | $-284.4M | ||
| Q2 24 | $-16.5M | $-433.6M | ||
| Q1 24 | $-26.5M | $-49.2M |
粗利率ARDXRILY
| Q4 25 | 91.3% | 79.5% | ||
| Q3 25 | 96.4% | 83.7% | ||
| Q2 25 | 87.3% | 81.3% | ||
| Q1 25 | 83.4% | 81.4% | ||
| Q4 24 | 84.3% | 79.8% | ||
| Q3 24 | 84.0% | 82.1% | ||
| Q2 24 | 87.1% | 84.5% | ||
| Q1 24 | 84.5% | 85.3% |
営業利益率ARDXRILY
| Q4 25 | 4.1% | 32.3% | ||
| Q3 25 | 4.2% | 30.4% | ||
| Q2 25 | -14.7% | 5.7% | ||
| Q1 25 | -49.0% | -31.2% | ||
| Q4 24 | 7.0% | -69.2% | ||
| Q3 24 | 2.3% | -36.4% | ||
| Q2 24 | -18.6% | -90.8% | ||
| Q1 24 | -53.6% | -6.1% |
純利益率ARDXRILY
| Q4 25 | -0.3% | 47.9% | ||
| Q3 25 | -0.9% | 42.3% | ||
| Q2 25 | -19.5% | 74.1% | ||
| Q1 25 | -55.5% | -5.1% | ||
| Q4 24 | 4.0% | -2.3% | ||
| Q3 24 | -0.8% | -126.1% | ||
| Q2 24 | -22.5% | -169.4% | ||
| Q1 24 | -57.6% | -18.7% |
EPS（希薄化後）ARDXRILY
| Q4 25 | $-0.01 | $2.78 | ||
| Q3 25 | $0.00 | $2.91 | ||
| Q2 25 | $-0.08 | $4.50 | ||
| Q1 25 | $-0.17 | $-0.39 | ||
| Q4 24 | $0.01 | $-0.01 | ||
| Q3 24 | $0.00 | $-9.39 | ||
| Q2 24 | $-0.07 | $-14.35 | ||
| Q1 24 | $-0.11 | $-1.71 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $68.0M | $226.6M |
| 総負債低いほど良い | $202.8M | $1.4B |
| 株主資本純資産 | $166.9M | $-171.5M |
| 総資産 | $501.6M | $1.7B |
| 負債/資本比率低いほどレバレッジが低い | 1.21× | — |
8四半期トレンド — 暦四半期で整列
現金・短期投資ARDXRILY
| Q4 25 | $68.0M | $226.6M | ||
| Q3 25 | $42.7M | $184.2M | ||
| Q2 25 | $90.0M | $267.4M | ||
| Q1 25 | $30.8M | $138.3M | ||
| Q4 24 | $64.9M | $146.9M | ||
| Q3 24 | $47.4M | $159.2M | ||
| Q2 24 | $41.9M | $236.9M | ||
| Q1 24 | $36.1M | $190.7M |
総負債ARDXRILY
| Q4 25 | $202.8M | $1.4B | ||
| Q3 25 | $202.1M | $1.3B | ||
| Q2 25 | $201.4M | $1.3B | ||
| Q1 25 | $151.3M | $1.4B | ||
| Q4 24 | $150.9M | $1.5B | ||
| Q3 24 | $100.7M | — | ||
| Q2 24 | $100.2M | — | ||
| Q1 24 | $99.8M | — |
株主資本ARDXRILY
| Q4 25 | $166.9M | $-171.5M | ||
| Q3 25 | $154.3M | $-260.5M | ||
| Q2 25 | $139.5M | $-351.7M | ||
| Q1 25 | $145.7M | $-496.8M | ||
| Q4 24 | $173.3M | $-488.2M | ||
| Q3 24 | $158.3M | $-497.6M | ||
| Q2 24 | $147.0M | $-218.3M | ||
| Q1 24 | $150.9M | $228.4M |
総資産ARDXRILY
| Q4 25 | $501.6M | $1.7B | ||
| Q3 25 | $486.2M | $1.7B | ||
| Q2 25 | $466.8M | $1.5B | ||
| Q1 25 | $410.2M | $1.5B | ||
| Q4 24 | $435.8M | $1.8B | ||
| Q3 24 | $367.9M | $2.2B | ||
| Q2 24 | $343.5M | $3.2B | ||
| Q1 24 | $342.4M | $5.0B |
負債/資本比率ARDXRILY
| Q4 25 | 1.21× | — | ||
| Q3 25 | 1.31× | — | ||
| Q2 25 | 1.44× | — | ||
| Q1 25 | 1.04× | — | ||
| Q4 24 | 0.87× | — | ||
| Q3 24 | 0.64× | — | ||
| Q2 24 | 0.68× | — | ||
| Q1 24 | 0.66× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $21.0M | $26.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $20.6M | — |
| FCFマージンFCF / 売上 | 16.4% | — |
| 設備投資強度設備投資 / 売上 | 0.3% | — |
| キャッシュ転換率営業CF / 純利益 | — | 0.29× |
| 直近12ヶ月FCF直近4四半期 | $-44.0M | — |
8四半期トレンド — 暦四半期で整列
営業キャッシュフローARDXRILY
| Q4 25 | $21.0M | $26.2M | ||
| Q3 25 | $365.0K | $-60.6M | ||
| Q2 25 | $-25.3M | $-25.6M | ||
| Q1 25 | $-38.5M | $184.0K | ||
| Q4 24 | $9.8M | $-2.7M | ||
| Q3 24 | $501.0K | $19.5M | ||
| Q2 24 | $-19.4M | $111.5M | ||
| Q1 24 | $-35.7M | $135.4M |
フリーキャッシュフローARDXRILY
| Q4 25 | $20.6M | — | ||
| Q3 25 | $209.0K | — | ||
| Q2 25 | $-26.0M | — | ||
| Q1 25 | $-38.8M | — | ||
| Q4 24 | $9.2M | — | ||
| Q3 24 | $364.0K | — | ||
| Q2 24 | $-19.5M | — | ||
| Q1 24 | $-35.9M | — |
FCFマージンARDXRILY
| Q4 25 | 16.4% | — | ||
| Q3 25 | 0.2% | — | ||
| Q2 25 | -26.6% | — | ||
| Q1 25 | -52.3% | — | ||
| Q4 24 | 7.9% | — | ||
| Q3 24 | 0.4% | — | ||
| Q2 24 | -26.7% | — | ||
| Q1 24 | -77.9% | — |
設備投資強度ARDXRILY
| Q4 25 | 0.3% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 0.7% | — | ||
| Q1 25 | 0.4% | — | ||
| Q4 24 | 0.5% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.2% | — | ||
| Q1 24 | 0.3% | — |
キャッシュ転換率ARDXRILY
| Q4 25 | — | 0.29× | ||
| Q3 25 | — | -0.66× | ||
| Q2 25 | — | -0.18× | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.11× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ARDX
| Product IBSRELA | $86.6M | 69% |
| Product XPHOZAH | $27.8M | 22% |
| Other | $10.8M | 9% |
| Non Cash Royalty Related To Sale Of Future Royalties | $1.4M | 1% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
